Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast and TMS for Motor Plasticity
NCT06457191Phase 1Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of roflumilast in major depressive disorder (MDD) (4 arms), sponsored by University of Calgary. Primary endpoint: Motor evoked potential amplitude. Started Nov 2024; status: active, not recruiting.
02
Drugs
roflumilast
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06457191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457191.